Biosimilar Development News

1. China's First Trastuzumab Biosimilar Han Quyou Approved By NMPA 8/14/2020
2. US Biosimilars Market Size To Reach $22,996M By 2027; Recent Scientific Discoveries Have Indicated Signs Of A Promising Future, Says Fortune Business Insights™ 8/13/2020

   The US Biosimilars Market size is projected to reach USD 22,966 million by the end of 2027. The presence of several large scale companies that are engaged in the research and development of efficient biosimilars will have a huge impact on the growth of the overall market in the foreseeable future.

3. Samsung Bioepis Announces Launch Of ONTRUZANT (trastuzumab) In Brazil For Early And Metastatic HER2-Overexpressing Breast Cancer 8/10/2020

   Samsung Bioepis Co., Ltd. today announced the launch of its first oncology treatment ONTRUZANT (trastuzumab), a biosimilar referencing HERCEPTINII , in Brazil. ONTRUZANT (150 mg single-dose vials) was approved by Agência Nacional de Vigilância Sanitária (ANVISA), the country’s health regulatory agency for the treatment of metastatic HER2-overexpressing breast cancer, early HER2-overexpressing breast cancer, and advanced gastric cancer.

4. Teva And Alvotech Announce Strategic Partnership To Collaborate In The U.S. Biosimilar Market 8/5/2020

   Teva Pharmaceutical Industries Ltd. and biopharmaceutical company Alvotech today announced that they have entered into an exclusive strategic partnership for the commercialization in the U.S. of five biosimilar product candidates.

5. COVID-19 Impacts: Biosimilar Monoclonal Antibodies (mAbs) Market Will Accelerate At A CAGR Of Over 30% Through 2020-2024|Increase In Prevalence Of Chronic Diseases To Boost Growth| Technavio 8/4/2020

   Technavio has been monitoring the biosimilar monoclonal antibodies (mAbs) market and it is poised to grow by USD 8.65 billion during 2020-2024, progressing at a CAGR of over 30% during the forecast period.

6. SC Remsima Will Need Cost-Effective Pricing To Further Erode The Shares Of Remicade, Says GlobalData 8/4/2020

   Following the news that the first subcutaneous (SC) formulation of Celltrion’s Remsima (infliximab-dyyb/CT-P13) was granted marketing authorization by the European Commission (EC) for all indications in adults for which the intravenous formulation is also approved^*, GlobalData notes that, in order for Celltrion to further erode market share of its rival Remicade - and other anti-TNF agents in Europe, it will have to be priced intelligently as cost effective biologics are favoured by payers and regulators in this region.

7. ICYMI: Experts Detail How Shared Savings Model For Biosimilars Could Provide Savings For Seniors, Patients And Medicare 7/31/2020

   As a shared savings model gains bipartisan traction among politicians, experts continue to tout the billions of dollars of savings potential for seniors, patients and Medicare. In a recent analysis, Alex Brill, Founder of Matrix Global Advisors (MGA), an economic consulting firm, and a Resident Fellow at American Enterprise Institute, found that a robust biosimilars market could save U.S. taxpayers billions annually.

8. Biocon And Voluntis Deal Aims To Personalize Treatment For Type 2 Diabetic Patients On Insulin, Says GlobalData 7/30/2020

   Biocon Sdn. Bhd., Malaysia, a subsidiary of Biocon Biologics, and digital therapeutics company Voluntis have recently announced a global collaboration agreement to develop and distribute FDA-cleared and CE-marked digital therapeutic product ‘Insulia’ for type 2 diabetes (T2D) patients across several markets.

9. Cadila Pharmaceuticals Launches Biosimilar Rituximab Drug Ritucad 7/29/2020

   Ahmedabad-based Cadila Pharmaceuticals Limited recently announced the launch of biosimilar Rituximab for Indian market. Biosimilar Rituximab is used for treatment of blood cancer and rheumatoid arthritis, and will be launched under the brand name Ritucad.

10. Henlius And Accord Healthcare Receive EMA Approval For Zercepac, trastuzumab Biosimilar 7/29/2020

    Shanghai Henlius Biotech, Inc. (2696.HK) and Accord Healthcare Limited (Accord) jointly announced the European Commission (EC) has approved Zercepac(HLX02), a trastuzumab biosimilar developed and manufactured by Henlius, for the treatment of HER2-positive early breast cancer, HER2-positive metastatic breast cancer and HER2-positive metastatic gastric cancer.